Evaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA® (pembrolizumab) in Patients with Melanoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. CRWV

Go back to Evaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA® (pembrolizumab) in Patients with Melanoma
(NASDAQ: EVAX) Delayed: 3.74 +0.13 (3.60%)
Previous Close $3.61    52 Week High $ 
Open $3.55    52 Week Low $ 
Day High $3.90    P/E N/A 
Day Low $3.55    EPS $ 
Volume 43,221